1.80Open1.80Pre Close0 Volume411 Open Interest2.50Strike Price0.00Turnover0.00%IV19.63%PremiumMay 16, 2025Expiry Date1.63Intrinsic Value100Multiplier5DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sutro Biopharma Stock Discussion
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Monday, 28th April at 4:05 pm
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (...
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future
Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026
No comment yet